| 引用本文: | 施红波,竺乖叶,庞亚娇,汪玲萍.甘草锌辅助治疗3~6岁支原体肺炎患儿的临床研究[J].中国现代应用药学,2014,31(3):369-372. |
| SHI Hongbo,ZHU Guaiye,PANG Yajiao,WANG Lingping.Clinical Analysis of Licorzinc in the Treatment of Mycoplasma Pneumonia in Children Aged 3-6[J].Chin J Mod Appl Pharm(中国现代应用药学),2014,31(3):369-372. |
|
| 摘要: |
| 目的 探讨甘草锌在治疗3~6岁儿童支原体肺炎中的临床意义及可能机制。方法 62例支原体肺炎住院患儿随机分为2组，对照组30人，予阿奇霉素及对症治疗，治疗组32人，在上述治疗基础上加用甘草锌口服治疗，观察患儿临床指标、免疫功能并随访6个月。结果 2组患儿临床转归无差异；治疗组出院后再次感染情况明显减少(Ρ<0.05)；治疗后2组IgA均升高、补体C3、补体C4均下降；与对照组相比，治疗后治疗组补体C4及CD8比例低，CD4比例高(Ρ<0.05)。结论 甘草锌辅助治疗支原体肺炎有助于减少并发反复呼吸道感染的危险，能更好地恢复机体的免疫平衡，无明显不良反应。 |
| 关键词: 甘草锌 支原体肺炎 体液免疫 细胞免疫 |
| DOI： |
| 分类号: |
| 基金项目:宁波市鄞州区科技局2010年区级社会发展科技计划项目(鄞科[2010]75号) |
|
| Clinical Analysis of Licorzinc in the Treatment of Mycoplasma Pneumonia in Children Aged 3-6 |
|
SHI Hongbo, ZHU Guaiye, PANG Yajiao, WANG Lingping
|
|
Department of Pediatrics, Ningbo Yinzhou People’s Hospital, Ningbo 315040, China
|
| Abstract: |
| OBJECTIVE To evaluate the clinical significance of licorzinc in the treatment of mycoplasma pneumonia(MPP) in children aged 3-6 and its possible mechanism. METHODS Sixty-two patients with MPP were randomly divided into 2 groups, 30 patients in control group were treated with azithromycin and symptomatic treatment; 32 patients in treatment group were treated with licorzinc besides conventional therapy. Then the clinical indexes, cell immunity and humoral immunity before and after treatment were observed. RESULTS The clinical effects in the two groups were equivalent(P>0.05). Recurrent respiratory tract infection significantly reduced in treatment group after six months follow-up(Ρ<0.05). IgA increased and complement C3 and C4 decreased in two groups after treatment, while CD8 increased in control group after treatment(Ρ<0.05). The level of complement C4 and CD8 were lower and CD4 was higher in treatment group compared after treatment (Ρ<0.05). CONCLUSION Licorzinc helps to reduce recurrent respiratory tract infection and restore the body's immune balance, and no adverse reaction is observed. |
| Key words: licorzinc mycoplasma pneumonia humoral immunity cell immunity |
